Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Welcome And What IN8bio Builds
- 2:09From Biochemist To Wall Street
- 5:46Crossover Rounds And IPO Access
- 12:04The Blizzard Lunch That Started It
- 16:59Why Gamma Delta T Cells Matter
- 21:31Picking GBM And Allo Versus Auto
- 30:33Racing The IPO Window In 2020-2021
- 41:17Restructuring And Leadership Under Stress
- 47:20New Financing And T Cell Engagers
- 48:49Investor Sentiment And In Vivo CAR-T Risks
- 52:20External Watchlist China And Data Trust
- 54:22Final Thoughts And Where To Follow